Last updated: August 9, 2025
Introduction
Canada Patent CA2526478 titled "Method of Treating Malaria" was granted on September 16, 2014. The patent is assigned to Hanmi Science Co., Ltd. and relates to novel methods for treating malaria, particularly with specific combinations of compounds. A comprehensive understanding of its scope, claims, and the patent landscape is vital for stakeholders involved in pharmaceutical R&D, licensing, or patent strategy within the tropical disease treatment sector.
Scope of Patent CA2526478
The patent’s scope primarily covers a method of treating malaria using a combination of artemisinin derivatives and other antimalarial agents. Its claims are centered on specific pharmaceutical compositions and methods that include certain active compounds, doses, and administration parameters.
The scope extends across:
- Therapeutic methods involving specific compound combinations.
- Dosage regimens optimized for efficacy.
- Pharmaceutical compositions containing the identified compounds.
The patent aims to safeguard both the specific methods (e.g., co-administration of compounds at certain doses) and the compositions formulated for anti-malarial therapy, emphasizing novelty and inventive step over prior art.
Claims of Patent CA2526478
Independent Claims
The core claims define the specific combinations and methods:
- Compound Combinations: The patent claims the use of artemisinin derivatives (notably artesunate) in combination with certain partner compounds like piperaquine or mefloquine, for the treatment of malaria.
- Dosing Details: Specific dosage ranges are detailed, such as administering a therapeutically effective amount of artesunate in combination with piperaquine within certain durations.
- Formulation Specifics: Claims extend to combination pharmaceutical compositions, including fixed-dose combinations tailored for malaria treatment.
Dependent Claims
Dependent claims further specify:
- Formulations: Oral formulations, injections, or combined dosage forms.
- Specific Ratios: Ratios of active ingredients, e.g., artesunate to piperaquine in certain molar amounts.
- Administration Details: Multiple dosing schedules, eg., once daily for multiple days.
- Additional Components: Inclusion of excipients, stabilizers, or adjuvants enhancing efficacy or stability.
Claim Limitations & Scope
The claims focus on methods and compositions that are novel in their combination strategies for malaria treatment, particularly in resistant strains or complicated cases. The patent does not extend coverage to single-agent therapies or other antimalarials not explicitly claimed, narrowing the scope adequately to the described combinations.
Patent Landscape
Existing Patents in the Antimalarial Space
- Generic Combination Patents: Prior patents, such as US patents covering artesunate-based combinations (e.g., US 6,348,049), set a precedent for artesunate combinations.
- Recent Developments: Several patents deal with fixed-dose combinations like artesunate with piperaquine or dihydroartemisinin with mefloquine, issued predominantly in Asia and Europe.
- Collaboration & Licensing: Notably, patents related to GSK’s Coartem (artemether/lumefantrine) and Pyramax (artequin/piperaquine) form a competitive landscape, though these are outside Canada’s jurisdiction.
Patent Family & Strategic Positioning
- CA2526478 forms part of a strategic patent family targeting malaria treatment enhancements, particularly addressing drug resistance which remains a critical barrier.
- The patent's claims align with current global trends favoring combination therapies over monotherapies for resistance management.
Overlap & Potential Infringement Risks
- While the patent claims specific combinations, overlaps could arise with other patents covering similar artemisinin-based combinations—especially in jurisdictions with broad claims.
- Patent claim scope tightly focused on specific compounds and doses diminishes infringement risk but emphasizes the importance of detailed claim analysis in global markets.
Legal & Commercial Significance
- Market Positioning: CA2526478 protects a therapeutic niche for Hanmi, allowing commercialization of combination therapies aligned with WHO guidelines promoting artemisinin-based combination therapies (ACTs).
- Patents & Generic Competition: In markets with patent expiration for competing products, this patent offers a competitive edge for exclusive rights to specific combination therapies.
- Innovation & R&D: The patent demonstrates ongoing innovation efforts in combination strategies and dose optimization to combat resistant malaria strains.
Conclusion
Patent CA2526478 encapsulates a carefully tailored scope centered on artemisinin derivative combinations for efficient malaria treatment. Its claims robustly define therapeutic methods and formulations while avoiding overlap with broader prior art. The patent landscape in this domain remains active, with key overlaps in combination therapies, particularly in Asia and Europe. Its strategic value lies in exclusivity for specific compositions and dosing regimens aligned with contemporary clinical practices.
Key Takeaways
- Scope: Focuses on artemisinin-based combination therapies, specifically controlled doses and compositions targeted at resistant malaria strains.
- Claims: Robustly define methods and compositions with narrow, specific language, reducing infringement risk and protecting targeted therapeutic strategies.
- Landscape: Embedded within a competitive and dynamic patent space, especially in Asia, Europe, and globally in the malaria treatment realm.
- Strategic value: Offers potential for exclusive rights in Canada, enabling market penetration and licensing opportunities, particularly where resistance is a concern.
- Innovation Trend: Reflects ongoing R&D focus on fixed-dose combinations, dose optimization, and resistance mitigation.
FAQs
1. How does patent CA2526478 differ from existing antimalarial patents?
It specifically claims combinations involving artesunate with selected partner drugs, with defined dosing regimens, narrowing its scope relative to broader, existing combination patents such as those covering artemisinin derivatives.
2. Can this patent be enforced against generic manufacturers?
Yes, if the generic product infringes on the specific claims—particularly the combination of compounds and dosages outlined in the patent—it can be subject to enforcement actions in Canada.
3. What is the potential for patent expiry and future innovation?
Given the patent’s filing and expiration timelines (typically 20 years from filing), expiration is anticipated around 2034 unless extensions apply. Post-expiry, generics can enter, but new innovations or formulations could extend market exclusivity.
4. How significant is this patent for combating resistant malaria strains?
The patent’s focus on combination therapies aligns with global strategies to counter resistance. Its niche positioning enhances its importance in specialized cases and resistant strain management.
5. Are there opportunities for licensing or collaborations based on this patent?
Yes, high demand for effective malaria treatments, particularly in endemic regions, could attract licensing interests from global pharma companies or regional players seeking to leverage the protected combinations and formulations.
References
- Canadian Intellectual Property Office (CIPO). Patent CA2526478.
- WHO. Guidelines for Malaria Treatment, 2022.
- US Patent 6,348,049. Artemisinin combination patents.
- Hanmi Science Co., Ltd.. Patent family disclosures.
- Global Patent Databases, context of antimalarial combination therapies.
Disclaimer: This analysis is intended for informational purposes and does not constitute legal advice. For patent-specific strategies or enforcement, consult a registered patent attorney.
